Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $90.4 million.

  • Biodesix's Total Liabilities rose 2077.56% to $90.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.4 million, marking a year-over-year increase of 2077.56%. This contributed to the annual value of $76.4 million for FY2024, which is 1920.1% down from last year.
  • As of Q3 2025, Biodesix's Total Liabilities stood at $90.4 million, which was up 2077.56% from $86.6 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Total Liabilities registered a high of $94.5 million during Q4 2023, and its lowest value of $53.9 million during Q1 2022.
  • Its 5-year average for Total Liabilities is $77.1 million, with a median of $76.2 million in 2023.
  • Per our database at Business Quant, Biodesix's Total Liabilities tumbled by 3185.67% in 2022 and then soared by 4153.15% in 2023.
  • Quarter analysis of 5 years shows Biodesix's Total Liabilities stood at $56.4 million in 2021, then increased by 28.26% to $72.3 million in 2022, then soared by 30.73% to $94.5 million in 2023, then fell by 19.2% to $76.4 million in 2024, then increased by 18.43% to $90.4 million in 2025.
  • Its Total Liabilities was $90.4 million in Q3 2025, compared to $86.6 million in Q2 2025 and $75.2 million in Q1 2025.